Targeting epithelial-mesenchymal transition signaling pathways with Dietary Phytocompounds and repurposed drug combinations for overcoming drug resistance in various cancers by A.N.K.V. Sravani, John Thomas

Subjects: Get full text

<italic>Hedyotis Diffusa</italic> Willd Increase Drugs Accumulation by Regulating Hedgehog Pathway in Drug Resistant Colorectal Cancer Cells by Yiyi JIN, Qiongyu LI, Zijun LAI, Zhaokun YAN, Jianyu FENG, Jiumao LIN

Subjects: Get full text

Outpatient chemotherapy drug costs and expensive chemotherapy drug use in 340B and Non-340B hospitals: an observational study by Jianhui Hu, David R. Nerenz

Subjects: Get full text

Exploring QSAR for Antimalarial Activities and Drug Distribution within Blood of a Series of 4-Aminoquinoline Drugs Using Genetic-MLR by Amir Najafi, Soheil Sobhanardakani, Mehdi Marjani

“…We obtained two different models against Chloroquine-sensitive (3D7) and Chloroquine-resistant (W2) strains of Plasmodium falciparum with good adjustment levels. Drug distribution in blood, defined as drug blood-to-plasma concentration ratio (Rb), is related to molecular descriptors. …”
Get full text

Prediction of drug-drug plasma protein binding interactions of resveratrol in combination with celecoxib and leflunomide by molecular docking combined with an ultrafiltration technique by Zhou Peng, Hua Fang

“…Molecular operating environment (MOE, 2008.10) software package was used to explore molecular interactions between the drugs and HSA. Molecular docking was adopted to predict the interactions between resveratrol and other drugs and then the ultrafiltration technique was used to verify the docking results. …”
Get full text

Anticancer Drugs Induced Severe Adverse Cutaneous Drug Reactions: An Updated Review on the Risks Associated with Anticancer Targeted Therapy or Immunotherapies by Chau Yee Ng, Chun-Bing Chen, Ming-Ying Wu, Jennifer Wu, Chih-Hsun Yang, Rosaline Chung-Yee Hui, Ya-Ching Chang, Chun-Wei Lu

“…Cutaneous adverse drug reactions are commonly seen in patients with anticancer drug treatment. …”
Get full text

Evaluation of Multiple Immunoassay Technology Platforms to Select the Anti-Drug Antibody Assay Exhibiting the Most Appropriate Drug and Target Tolerance by Justine Collet-Brose, Pierre-Jean Couble, Maureen R. Deehan, Robert J. Nelson, Walter G. Ferlin, Sabrina Lory

“…An acid dissociation step successfully improved the drug tolerance for all 4 technology platforms and the required drug tolerance was achieved with the Gyrolab and MSD platforms. …”
Get full text

Editorial: Biologic drugs in immune-mediated inflammatory diseases, validation, drug-utilization, effectiveness, regulation, costs, and safety in the real-world by Irma Convertino, Luciane Cruz Lopes, Nicole Pratt, Ylenia Ingrasciotta, Marco Tuccori

Subjects: “…biologic drugs…”
Get full text

Risk Factors and Patterns of Drug‐Drug Interactions in Two Categories of Level‐3 Hospitals in Dhaka: A Cross‐Sectional Study by Md. Abdus Samadd, Farhan Tanvir Patwary, Md Momin Islam, Ashfia Tasnim Munia, K. M. Yasif Kayes Sikdar, Md. Raihan Sarkar

Subjects: “…drug‐drug interactions…”
Get full text

Prevalence of potential drug‒drug interactions and associated factors among elderly patients in Ethiopia: a systematic review and meta-analysis by Tekletsadik Tekleslassie Alemayehu, Yilkal Abebaw Wassie, Abaynesh Fentahun Bekalu, Addisu Afrassa Tegegne, Wondim Ayenew, Gebresilassie Tadesse, Demis Getachew, Abebaw Setegn Yazie, Bisrat Birke Teketelew, Mekonnen Derese Mekete, Setegn Fentahun, Tesfaye Birhanu Abebe, Tefera Minwagaw, Gebremariam Wulie Geremew

Subjects: Get full text

Reducing men’s health drug costs: exploring the impact of the Mark Cuban Cost Plus Drug Company model on Medicare savings by Adam Khan, Karim Kari, Eli Oldham, Jacob Duncan, Matthew Rashid, Matt Vassar

Subjects: Get full text

Association of expedited review programmes with postmarketing safety events of new drugs approved by the US food and drug administration between 2007 and 2017 by Bao Liu, Xingyue Zhu

“…Objective To explore the associations between the risks of postmarketing safety events of new drugs and the four expedited programmes of priority review, accelerated approval, fast track and breakthrough therapy established by the US Food and Drug Administration (FDA); and to investigate whether multiple uses of expedited programmes, and the combinations of expedited programmes with orphan designation, were relevant to different safety profiles.Design Cohort study.Setting USA.Participants All new drugs approved by the FDA between 1 January 2007 and 31 December 2017, followed up until 10 April 2021.Outcome measures Safety events included safety-related withdrawal, new boxed warning, drug safety communication, postapproval risk evaluation mitigation strategy and safety-related labelling changes. …”
Get full text

Work loss in patients with rheumatoid arthritis treated with abatacept, rituximab, tocilizumab or TNF inhibitors: a nationwide direct drug-to-drug comparison by Ulf Lindström, Johan Askling, Katerina Chatzidionysiou, Lotta Ljung, Lars Klareskog, Martin Neovius, Nils Feltelius, Eva Baecklund, Christopher Sjöwall, Helena Forsblad-d’Elia, Carl Turesson, Elisabet Lindqvist, Thomas Frisell, Alf Kastbom, Helena Forsblad-d'Elia, Jonas Söderling, Ann Knight, Gerd-Marie Alenius, Gustaf Magnus Bruze

“…Patients in the different treatment arms were balanced regarding baseline covariates using inverse probability weighting (IPTW).Results Work loss increased for patients with RA until drug treatment initiation, reached a peak in the month after treatment initiation and then levelled off. …”
Get full text

A retrospective study on potential drug‒drug interactions in patients with severe asthma receiving biological therapy: a single-center experience by Mirna Momcilovic, Petra Turcic, Franka Butkovic, Sanja Popovic Grle

Subjects: Get full text

Recent evidence comparing combination of conventional synthetic disease-modifying antirheumatic drugs with biologic disease-modifying antirheumatic drugs in rheumatoid arthritis by Abhishek Zanwar, Sakir Ahmed, Durga Prasanna Misra, Vikas Agarwal, Aman Sharma, Anupam Wakhlu, Vir Singh Negi

Subjects: “…Biologic disease-modifying antirheumatic drug…”
Get full text

Correction: Prevalence of potential drug‒drug interactions and associated factors among elderly patients in Ethiopia: a systematic review and meta-analysis by Tekletsadik Tekleslassie Alemayehu, Yilkal Abebaw Wassie, Abaynesh Fentahun Bekalu, Addisu Afrassa Tegegne, Wondim Ayenew, Gebresilassie Tadesse, Demis Getachew, Abebaw Setegn Yazie, Bisrat Birke Teketelew, Mekonnen Derese Mekete, Setegn Fentahun, Tesfaye Birhanu Abebe, Tefera Minwagaw, Gebremariam Wulie Geremew

Get full text

Risk Factors Analysis of Cutaneous Adverse Drug Reactions Caused by Targeted Therapy and Immunotherapy Drugs for Oncology and Establishment of a Prediction Model by Zimin Zhang, Mingyang Zhu, Weiwei Jiang

Subjects: “…cutaneous adverse drug reactions…”
Get full text

Peculiarities of personalized selection of antipsychotic drugs for schizophrenia treatment by O.O. Khaustova, A.E. Asanova, N.O. Dzeruzhynska, M.M. Matiash

“…Determining the optimal antipsychotic drugs, its effective dose, duration of therapy, form, and route of administration play a key role in the treatment of schizophrenia. …”
Get full text

The Impacts of Breakthrough Drug Classes on Total Healthcare Expenditures by Zeynal Karaca, Steven N. Wiggins

“…The costs and benefits of these newer and more expensive drugs, however, are controversial. The empirical evidence on whether newer drugs can decrease overall healthcare expenditures may enable private and public health policymakers to develop new drug benefit structures. …”
Get full text

Assessing the health implications of anticholinergic drugs in older people by Mariangela Boccardi, Virginia Boccardi

Subjects: Get full text